- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Melanocytes.
Displaying page 1 of 1.
EudraCT Number: 2010-019994-13 | Sponsor Protocol Number: RD.03.SPR.40117E | Start Date*: 2010-09-21 | |||||||||||
Sponsor Name:GALDERMA R&D | |||||||||||||
Full Title: EXPLORATORY STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CD07387 SOLUTION IN PATIENTS WITH VITILIGO | |||||||||||||
Medical condition: Vitiligo | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001731-20 | Sponsor Protocol Number: ML29741 | Start Date*: 2016-03-09 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A SINGLE ARM, OPEN LABEL, PHASE II, MULTICENTER STUDY TO ASSESS THE DETECTION OF THE BRAF V600 MUTATION ON cfDNA FROM PLASMA IN PATIENTS WITH ADVANCED MELANOMA | |||||||||||||
Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002454-36 | Sponsor Protocol Number: 2125-MEL-301 | Start Date*: 2018-04-28 | |||||||||||
Sponsor Name:Idera Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma | |||||||||||||
Medical condition: Refractory melanoma is a malignant tumor of melanocytes which originates predominantly from skin. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003864-30 | Sponsor Protocol Number: APX005M-010 | Start Date*: 2019-02-08 | |||||||||||
Sponsor Name:Apexigen, Inc. | |||||||||||||
Full Title: A Study to Evaluate the Safety and efficacy of the CD40 Agonistic Antibody APX005M in Adults with Immunotherapy Naive Metastatic Melanoma | |||||||||||||
Medical condition: Unresectable or metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001906-61 | Sponsor Protocol Number: 20180115 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy | |||||||||||||
Medical condition: Unresectable/Metastatic Stage IIIB-IVM1d Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GR (Completed) PL (Prematurely Ended) ES (Ongoing) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016909-42 | Sponsor Protocol Number: | Start Date*: 2010-11-19 | |||||||||||
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | |||||||||||||
Full Title: Effect of topical imiquimod on lentigo maligna. | |||||||||||||
Medical condition: lentigo maligna | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004387-18 | Sponsor Protocol Number: CO39722 | Start Date*: 2018-01-09 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED AD... | |||||||||||||
Medical condition: Metastatic BRAFV600 wild-type melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) GR (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000759-41 | Sponsor Protocol Number: MO39136 | Start Date*: 2018-08-30 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZU... | |||||||||||||
Medical condition: Metastatic Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) HU (Completed) ES (Completed) DE (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000631-23 | Sponsor Protocol Number: BP43963 | Start Date*: 2022-11-03 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY OF MULTIPLE DOSES OF RO7247669 IN PARTICIPANTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC MELANOMA | |||||||||||||
Medical condition: Unresectable or Metastatic Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) SK (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003866-14 | Sponsor Protocol Number: APX005M-002 | Start Date*: 2019-02-28 | ||||||||||||||||
Sponsor Name:Apexigen, Inc. | ||||||||||||||||||
Full Title: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastati... | ||||||||||||||||||
Medical condition: Non-small Cell Lung Cancer and Metastatic Melanoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001773-24 | Sponsor Protocol Number: GO40558 | Start Date*: 2019-12-05 | |||||||||||||||||||||||||||||||
Sponsor Name:Genentech Inc. | |||||||||||||||||||||||||||||||||
Full Title: A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED M... | |||||||||||||||||||||||||||||||||
Medical condition: Advanced melanoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) BE (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002147-29 | Sponsor Protocol Number: BO43328 | Start Date*: 2021-11-30 | |||||||||||
Sponsor Name:Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA | |||||||||||||
Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) NL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.